Haemonetics Corporation
US ˙ NYSE ˙ US4050241003

SecurityHAE / Haemonetics Corporation
InstitutionSilvercrest Asset Management Group Llc
Latest Disclosed Ownership491,747 shares
Latest Disclosed Value $ 27,715,026
Silvercrest Asset Management Group Llc reports 14.28% decrease in ownership of HAE / Haemonetics Corporation

On May 15, 2026 - Silvercrest Asset Management Group Llc filed a 13F-HR form disclosing ownership of 491,747 shares of Haemonetics Corporation (US:HAE) valued at $27,714,861 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 573,653 shares of Haemonetics Corporation. This represents a change in shares of -14.28% during the quarter. The current value of the position is $32,396,292 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F HAEMONETICS CORP COM COM 405024100 491,747 -81,906 -14.28 27,715 -39.72 0.2003
2026-02-17 2025-12-31 13F HAEMONETICS CORP COM COM 405024100 573,653 -67,969 -10.59 45,979 47.03 0.3160
2025-11-14 2025-09-30 13F HAEMONETICS CORP COM COM 405024100 641,622 43,212 7.22 31,273 -29.96 0.2069
2025-08-14 2025-06-30 13F HAEMONETICS COM 405024100 598,410 -33,606 -5.32 44,648 11.16 0.2999
2025-05-15 2025-03-31 13F HAEMONETICS COM 405024100 632,016 -11,211 -1.74 40,165 -20.03 0.2875
2025-02-14 2024-12-31 13F HAEMONETICS COM 405024100 643,227 152,042 30.95 50,223 27.21 0.3355
2024-11-14 2024-09-30 13F HAEMONETICS CORP COM COM 405024100 491,185 -6,904 -1.39 39,481 -4.19 0.2686
2024-08-15 2024-06-30 13F/A-1 HAEMONETICS CORP COM COM 405024100 498,089 44,595 9.83 41,207 6.46 0.2827
2024-08-14 2024-06-30 13F HAEMONETICS CORP COM COM 405024100 996,178 542,684 82,414 0.1884
2024-05-15 2024-03-31 13F HAEMONETICS CORP COM COM 405024100 453,494 453,494 38,706 0.2619
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.